Pan-cancer analysis of UDP-glucose 6-dehydrogenase in human tumors and its function in hepatocellular carcinoma

Figure 5 Correlations between UDP-glucose 6-dehydrogenase expression and immune subtypes in 9 cancers. A: Correlations between UDP-glucose 6-dehydrogenase (UGDH) expression and immune subtypes in ACC; B: Correlations between UGDH expression and immune subtypes in BRCA; C: Correlations between UGDH expression and immune subtypes in KIRC; D: Correlations between UGDH expression and immune subtypes in KIRP; E: Correlations between UGDH expression and immune subtypes in LIHC; F: Correlations between UGDH expression and immune subtypes in LUAD; G: Correlations between UGDH expression and immune subtypes in SARC; H: Correlations between UGDH expression and immune subtypes in SKCM; I: Correlations between UGDH expression and immune subtypes in UCS. C1 (wound healing), C2 (IFN-γ dominant), C3 (inflammatory), C4 (lymphocyte-depleted), C5 (immunologically quiet), and C6 (TGF-β dominant).